Celgene Co. (CELG) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 99.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,545 shares of the biopharmaceutical company’s stock after selling 414,720 shares during the quarter. Teacher Retirement System of Texas’ holdings in Celgene were worth $240,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Bruderman Asset Management LLC bought a new position in shares of Celgene during the 4th quarter worth $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth about $25,000. Athena Capital Advisors LLC acquired a new stake in Celgene during the fourth quarter worth about $27,000. Investors Research Corp acquired a new stake in Celgene during the first quarter worth about $28,000. Finally, Liberty Wealth Management LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $29,000. Institutional investors own 70.78% of the company’s stock.

Shares of NASDAQ CELG traded down $0.60 during trading on Thursday, hitting $95.76. The stock had a trading volume of 230,168 shares, compared to its average volume of 4,854,612. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.07. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. The firm has a market cap of $67.96 billion, a price-to-earnings ratio of 12.58, a PEG ratio of 0.44 and a beta of 1.68.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 earnings per share. On average, research analysts anticipate that Celgene Co. will post 9.85 EPS for the current fiscal year.

Several analysts have commented on CELG shares. Mizuho set a $103.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday, April 5th. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a research report on Friday, May 3rd. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research report on Friday, February 1st. William Blair downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Monday, April 1st. Finally, Atlantic Securities downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 price objective on the stock. in a report on Monday, April 1st. Twenty analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $95.96.

COPYRIGHT VIOLATION NOTICE: “Celgene Co. (CELG) Shares Sold by Teacher Retirement System of Texas” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/celgene-co-celg-shares-sold-by-teacher-retirement-system-of-texas.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: Cryptocurrencies

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.